Physician profile
George Kim
NPI 1316936040
$361,024.39
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $205K · 2020: $57K · 2021: $81K · 2022: $18K · 2023: $113 · 2024: $203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $317.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $316.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $148,462.95 | 2019-2022 | |
| Amgen INC. | $67,491.82 | 2019-2020 | |
| Eisai INC. | $48,707.06 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $30,571.40 | 2019-2021 | |
| Celgene Corporation | $24,571.30 | 2019-2020 | |
| Coherus Oncology, INC. | $19,307.62 | 2021-2024 | |
| Exelixis INC. | $8,838.18 | 2019-2022 | |
| Eli Lilly and Company | $8,123.78 | 2019 | |
| Agios Pharmaceuticals, INC. | $4,028.92 | 2019 | |
| Daiichi Sankyo INC. | $417.65 | 2021 | |
| Boston Scientific Corporation | $151.42 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $135.00 | 2024 | Imfinzi |
| Array Biopharma INC | $97.24 | 2019 | |
| Beigene USA, INC. | $64.02 | 2020 | |
| Servier Pharmaceuticals LLC | $56.03 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.